[FG] Kyburz Diego

Research Focus

Immunology & Infectious Diseases

Area of Research

Experimental Rheumatology

Approved Research Projects

• Exploring Novel Mechanisms In Autoimmune And Inflammatory Diseases-BASICHR0003

Novartis Pharma Schweiz AG, 11.2020-10.2022 (24)

PI : Kyburz, Diego DKF

• A Randomized Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Eli Lilly, 07.2019-06.2022 (36)

CI : Kyburz, Diego DKF

• A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional

Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Abbvie AG, 05.2018-04.2021 (36)

PI : Kyburz, Diego DKF

• Identification of biomarkers and therapeutic targets in inflammatory disease immunotherapy by high-dimensional single cell analysis and cluster proteomics

Swiss Personalized Health Network (SAMW), 02.2018-01.2021 (36)

CI : Kyburz, Diego DKF

• EXPLORING NOVEL MECHANISMS IN AUTOIMMUNE AND INFLAMMATORY DISEASES

Novartis Pharma, 11.2018-10.2020 (24)

PI : Kyburz, Diego DKF

• EXPLORING NOVEL MECHANISMS IN AUTOIMMUNE AND INFLAMMATORY DISEASES

Novartis Pharma, 12.2016-11.2018 (24)

PI : Kyburz, Diego DKF

• Patients with autoimmune diseases

Hoffmann-La Roche, 09.2016-08.2018 (24)

PI : Kyburz, Diego DKF

• Prospective observational study entitled “TofaSwiss Study - A Real Life Experience with tofacitinib. Data from the Swiss SCQM registry

SCQM Foundation, 09.2015-08.2017 (24)

PI : Kyburz, Diego DKF

• Randomized double blind Placebo controlled Phase III multicenter study of sc secukinumab in patients with active ankylosing spondylitis

Novartis Pharma, 11.2013-07.2017 (45)

PI : Kyburz, Diego DKF

• ASCORE Studie: Langzeiterfahrungen mit Abatacept sc in der täglichen Praxis

BMS (Bristol-Myers Squibb), 11.2013-04.2017 (42)

PI : Kyburz, Diego DKF

• A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

Abbvie AG, 03.2016-02.2017 (12)

PI : Kyburz, Diego DKF

Collaborations

National Collaborations

• Swiss Clinical Quality Management in Rheumatic Diseases (SCQM): national registry for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, giant cell arteritis, polymyalgia rheumatica. Established collaboration with the Swiss university centers and contributing hospitals.

International Collaborations

• EUSTAR: European registry for systemic sclerosis

Ongoing Research Projects

SCQM studies

• Comparative effectiveness of JAK inhibitor versus TNF inhibitor therapy in patients with RA who have discontinued a previous JAK inhibitor, PI Diego Kyburz
• Predictors for loss of productivity and the effect of b/tsDMARD treatment on loss of productivity in Swiss patients with rheumatoid arthritis, PI Diego Kyburz

Translational studies

• Identification of biomarkers prediction transition from psoriasis to psoriatic arthritis.Research collaboration with industry (agreement pending), PI Diego Kyburz / Tobias Manigold
• Extracellular vesicle analysis in synovial fluid from patients with RA and osteoarthritis (OA), PI Diego Kyburz
• The role of urate and calcium pyrophosphate crystals in the activation of macrophages in gout and pseudogout, PI Diego Kyburz

Multicenter clinical trials

• Participation in various phase II, III and IV studies in RA, spondyloarthritis, systemic lupus erythematosus, giant cell arteritis. Local PI Diego Kyburz, Thomas Daikeler, Ulrich Walker.